Header Logo

Connection

JOSEPH KHOURY to Humans

Back to Details
This is a "connection" page, showing publications JOSEPH KHOURY has written about Humans.
JOSEPH KHOURY
Connection Strength
1.707
Humans
  1. Can molecular patterns help to classify overlapping entities in myeloid neoplasms? Histopathology. 2025 Jan; 86(1):146-157.
    View in: PubMed
    Score: 0.019
  2. The Journey to Improve the College of American Pathologists Cancer Biomarker Reporting Protocols. Arch Pathol Lab Med. 2024 Oct 01; 148(10):1105-1109.
    View in: PubMed
    Score: 0.019
  3. Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope. Leuk Res. 2024 02; 137:107441.
    View in: PubMed
    Score: 0.018
  4. WHO or International Consensus Classification: Is the Difference Worth It? J Clin Oncol. 2023 11 01; 41(31):4937-4938.
    View in: PubMed
    Score: 0.017
  5. Response to the Comments from the Groupe Francophone de Cytog?n?tique H?matologique (GFCH) on the 5th edition of the World Health Organization classification of haematolymphoid tumors. Leukemia. 2023 05; 37(5):1170-1172.
    View in: PubMed
    Score: 0.017
  6. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma?variant. Virchows Arch. 2023 Jun; 482(6):1011-1019.
    View in: PubMed
    Score: 0.017
  7. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology. 2023 Jun; 55(4):514-524.
    View in: PubMed
    Score: 0.017
  8. Juvenile myelomonocytic leukemia; moving forward. Leukemia. 2023 03; 37(3):720-722.
    View in: PubMed
    Score: 0.017
  9. Where diagnosis for myelodysplastic neoplasms (MDS) stands today and where it will go: The role of flow cytometry in evaluation of MDS. Cytometry B Clin Cytom. 2023 01; 104(1):12-14.
    View in: PubMed
    Score: 0.017
  10. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood. 2022 07 07; 140(1):58-72.
    View in: PubMed
    Score: 0.016
  11. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic?Neoplasms. Leukemia. 2022 07; 36(7):1703-1719.
    View in: PubMed
    Score: 0.016
  12. Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy. Leuk Res. 2022 07; 118:106860.
    View in: PubMed
    Score: 0.016
  13. Artificial intelligence-assisted mapping of proliferation centers allows the distinction of accelerated phase from large cell transformation in chronic lymphocytic leukemia. Mod Pathol. 2022 08; 35(8):1121-1125.
    View in: PubMed
    Score: 0.016
  14. Microsatellite Instability Assessment by Immunohistochemistry in Acute Myeloid Leukemia: A Reappraisal and Review of the Literature. Clin Lymphoma Myeloma Leuk. 2022 06; 22(6):e386-e391.
    View in: PubMed
    Score: 0.016
  15. Future of Education or Present Reality? Arch Pathol Lab Med. 2021 11 01; 145(11):1350-1354.
    View in: PubMed
    Score: 0.015
  16. Artificial intelligence strategy integrating morphologic and architectural biomarkers provides robust diagnostic accuracy for disease progression in chronic lymphocytic leukemia. J Pathol. 2022 01; 256(1):4-14.
    View in: PubMed
    Score: 0.015
  17. B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL. Br J Haematol. 2021 09; 194(6):1034-1038.
    View in: PubMed
    Score: 0.015
  18. Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon. Leuk Lymphoma. 2021 12; 62(13):3296-3299.
    View in: PubMed
    Score: 0.015
  19. CD94 expression patterns in reactive and neoplastic T-cell and NK-cell proliferations. Leuk Res. 2021 09; 108:106614.
    View in: PubMed
    Score: 0.015
  20. B acute lymphoblastic leukemia arising during maintenance therapy for multiple myeloma. Blood. 2020 12 03; 136(23):2720.
    View in: PubMed
    Score: 0.014
  21. Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia. Am J Surg Pathol. 2020 09; 44(9):1235-1243.
    View in: PubMed
    Score: 0.014
  22. Immunopathology of Kikuchi-Fujimoto disease: A reappraisal using novel immunohistochemistry markers. Histopathology. 2020 Aug; 77(2):262-274.
    View in: PubMed
    Score: 0.014
  23. Myeloid diseases in the lung and pleura. Semin Diagn Pathol. 2020 Nov; 37(6):296-302.
    View in: PubMed
    Score: 0.014
  24. Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. Am J Surg Pathol. 2019 10; 43(10):1429-1437.
    View in: PubMed
    Score: 0.013
  25. Immunohistochemistry Innovations for Diagnosis and Tissue-Based Biomarker Detection. Curr Hematol Malig Rep. 2019 10; 14(5):368-375.
    View in: PubMed
    Score: 0.013
  26. Circulating Tumor Cells: State-of-the-art Update on Technologies and Clinical Applications. Curr Hematol Malig Rep. 2019 10; 14(5):353-357.
    View in: PubMed
    Score: 0.013
  27. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol. 2019 08; 186(4):538-548.
    View in: PubMed
    Score: 0.013
  28. Blastic plasmacytoid dendritic cell neoplasm with unusual lymphoid features and macrovacuoles. Ann Hematol. 2019 Sep; 98(9):2221-2222.
    View in: PubMed
    Score: 0.013
  29. Recent Updates on Chronic Myelomonocytic Leukemia. Curr Hematol Malig Rep. 2018 12; 13(6):446-454.
    View in: PubMed
    Score: 0.013
  30. Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria. Curr Hematol Malig Rep. 2018 12; 13(6):467-476.
    View in: PubMed
    Score: 0.013
  31. Blastic Plasmacytoid Dendritic Cell Neoplasm. Curr Hematol Malig Rep. 2018 12; 13(6):477-483.
    View in: PubMed
    Score: 0.013
  32. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia. Haematologica. 2019 04; 104(4):749-755.
    View in: PubMed
    Score: 0.013
  33. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens. Blood Cancer J. 2018 10 19; 8(11):98.
    View in: PubMed
    Score: 0.012
  34. P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. Am J Hematol. 2018 11; 93(11):1376-1383.
    View in: PubMed
    Score: 0.012
  35. Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. Leuk Res. 2018 10; 73:86-94.
    View in: PubMed
    Score: 0.012
  36. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv. 2018 08 14; 2(15):1807-1816.
    View in: PubMed
    Score: 0.012
  37. Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations. Am J Surg Pathol. 2018 06; 42(6):799-806.
    View in: PubMed
    Score: 0.012
  38. Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma. Am J Surg Pathol. 2018 04; 42(4):492-499.
    View in: PubMed
    Score: 0.012
  39. Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools. Eur J Haematol. 2018 May; 100(5):444-454.
    View in: PubMed
    Score: 0.012
  40. Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. Clin Cancer Res. 2018 02 01; 24(3):521-531.
    View in: PubMed
    Score: 0.012
  41. Response to Dr. Bain's comment on our review article: Pure Erythroid Leukemia. Am J Hematol. 2017 10; 92(10):E622.
    View in: PubMed
    Score: 0.012
  42. CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lympho-proliferation. Am J Hematol. 2017 10; 92(10):1113-1114.
    View in: PubMed
    Score: 0.011
  43. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica. 2017 10; 102(10):1661-1670.
    View in: PubMed
    Score: 0.011
  44. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm. Am J Hematol. 2017 Jun; 92(6):520-528.
    View in: PubMed
    Score: 0.011
  45. Langerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergence. Blood. 2017 03 16; 129(11):1563.
    View in: PubMed
    Score: 0.011
  46. Pure erythroid leukemia. Am J Hematol. 2017 03; 92(3):292-296.
    View in: PubMed
    Score: 0.011
  47. Histiocytic sarcoma: secondary neoplasm or "transdifferentiation" in the setting of B-acute lymphoblastic leukemia. Blood. 2016 11 17; 128(20):2475.
    View in: PubMed
    Score: 0.011
  48. Starry Sky Pattern in Hematopoietic Neoplasms: A Review of Pathophysiology and Differential Diagnosis. Adv Anat Pathol. 2016 Nov; 23(6):343-355.
    View in: PubMed
    Score: 0.011
  49. Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2016 10; 91(10):1036-43.
    View in: PubMed
    Score: 0.011
  50. The evolving potential of companion diagnostics. Scand J Clin Lab Invest Suppl. 2016; 245:S22-5.
    View in: PubMed
    Score: 0.011
  51. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016 Apr 14; 127(15):1863-9.
    View in: PubMed
    Score: 0.010
  52. High-grade Transformation of Low-grade B-cell Lymphoma: Pathology and Molecular Pathogenesis. Am J Surg Pathol. 2016 Jan; 40(1):e1-16.
    View in: PubMed
    Score: 0.010
  53. Disseminated blastic plasmacytoid dendritic cell neoplasm. Blood. 2015 Jul 23; 126(4):558.
    View in: PubMed
    Score: 0.010
  54. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. Br J Haematol. 2015 Oct; 171(1):91-9.
    View in: PubMed
    Score: 0.010
  55. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. J Hematol Oncol. 2015 Jun 10; 8:65.
    View in: PubMed
    Score: 0.010
  56. Acute Myeloid Leukemia With t(v;5q33) Is Associated With Poor Overall Survival and Often Lacks Myelodysplastic Features. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl:S85-90.
    View in: PubMed
    Score: 0.010
  57. Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment. Leukemia. 2016 Jan; 30(1):242-7.
    View in: PubMed
    Score: 0.010
  58. Unusual breast mass: lymphoma with crystal-storing histiocytosis. Blood. 2015 Apr 09; 125(15):2445.
    View in: PubMed
    Score: 0.010
  59. Next-generation companion diagnostics: promises, challenges, and solutions. Arch Pathol Lab Med. 2015 Jan; 139(1):11-3.
    View in: PubMed
    Score: 0.010
  60. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014 Oct 04; 7:74.
    View in: PubMed
    Score: 0.009
  61. Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia. J Hematol Oncol. 2014 Mar 27; 7:26.
    View in: PubMed
    Score: 0.009
  62. BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS. Am J Hematol. 2014 May; 89(5):499-504.
    View in: PubMed
    Score: 0.009
  63. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013 Dec; 88(12):1055-61.
    View in: PubMed
    Score: 0.009
  64. Landscape of DNA virus associations across human malignant cancers: analysis of 3,775 cases using RNA-Seq. J Virol. 2013 Aug; 87(16):8916-26.
    View in: PubMed
    Score: 0.009
  65. Intramedullary PNET of the spine: long-term survival after combined modality therapy and subsequent relapse. J Pediatr Hematol Oncol. 2011 Mar; 33(2):107-12.
    View in: PubMed
    Score: 0.007
  66. Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer. Am J Clin Pathol. 2010 Dec; 134(6):964-9.
    View in: PubMed
    Score: 0.007
  67. Grading of nonrhabdomyosarcoma soft tissue sarcoma in children and adolescents: a comparison of parameters used for the F?d?ration Nationale des Centers de Lutte Contre le Cancer and Pediatric Oncology Group Systems. Cancer. 2010 May 01; 116(9):2266-74.
    View in: PubMed
    Score: 0.007
  68. Dramatically elevated circulating tumor cell numbers in a patient with small cell neuroendocrine carcinoma of the prostate. Arch Pathol Lab Med. 2010 Jan; 134(1):120-3.
    View in: PubMed
    Score: 0.007
  69. Images in HIV/AIDS. HIV and myelodysplasia. AIDS Read. 2009 Apr; 19(4):156-7.
    View in: PubMed
    Score: 0.006
  70. Epstein-Barr virus in lymphoproliferative processes: an update for the diagnostic pathologist. Adv Anat Pathol. 2009 Jan; 16(1):40-55.
    View in: PubMed
    Score: 0.006
  71. ICAM-2 expression mediates a membrane-actin link, confers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma. PLoS One. 2008; 3(11):e3629.
    View in: PubMed
    Score: 0.006
  72. Call for revision of College of American Pathologists-mandated requirements for retention of laboratory records and materials. Arch Pathol Lab Med. 2008 Nov; 132(11):1712-3; discussion 1713.
    View in: PubMed
    Score: 0.006
  73. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer. 2008 Sep 15; 113(6):1453-61.
    View in: PubMed
    Score: 0.006
  74. Ewing sarcoma family of tumors: a model for the new era of integrated laboratory diagnostics. Expert Rev Mol Diagn. 2008 Jan; 8(1):97-105.
    View in: PubMed
    Score: 0.006
  75. Antiinflammatory adaptation to hypoxia through adenosine-mediated cullin-1 deneddylation. J Clin Invest. 2007 Mar; 117(3):703-11.
    View in: PubMed
    Score: 0.006
  76. Ewing sarcoma-family tumors that arise after treatment of primary childhood cancer. Cancer. 2006 Jul 01; 107(1):201-6.
    View in: PubMed
    Score: 0.005
  77. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Mod Pathol. 2006 Sep; 19(9):1213-20.
    View in: PubMed
    Score: 0.005
  78. STAT3 is activated in a subset of the Ewing sarcoma family of tumours. J Pathol. 2006 Apr; 208(5):624-32.
    View in: PubMed
    Score: 0.005
  79. Ewing sarcoma family of tumors. Adv Anat Pathol. 2005 Jul; 12(4):212-20.
    View in: PubMed
    Score: 0.005
  80. Nephroblastic neoplasms. Clin Lab Med. 2005 Jun; 25(2):341-61, vi-vii.
    View in: PubMed
    Score: 0.005
  81. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer. 2005 Mar 15; 103(6):1317-8; author reply 1318.
    View in: PubMed
    Score: 0.005
  82. Integrative immunophenotypic and genetic characterization of acute myeloid leukemia with CBFB rearrangement. Am J Clin Pathol. 2024 Nov 04; 162(5):455-463.
    View in: PubMed
    Score: 0.005
  83. Optical Genome Mapping for Detection of BCR::ABL1-Another Tool in Our Toolbox. Genes (Basel). 2024 Oct 22; 15(11).
    View in: PubMed
    Score: 0.005
  84. CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3?/ZAP70 Signaling Axis. Cancer Discov. 2024 Oct 04; 14(10):1879-1900.
    View in: PubMed
    Score: 0.005
  85. Methylation of SHP1 gene and loss of SHP1 protein expression are frequent in systemic anaplastic large cell lymphoma. Blood. 2004 Sep 01; 104(5):1580-1.
    View in: PubMed
    Score: 0.005
  86. Identification of circulating tumor cells captured by the FDA-cleared Parsortix? PC1 system from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluations. J Exp Clin Cancer Res. 2024 Aug 21; 43(1):240.
    View in: PubMed
    Score: 0.005
  87. Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma. Oncoimmunology. 2024; 13(1):2388304.
    View in: PubMed
    Score: 0.005
  88. Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. 2024 07 04; 144(1):61-73.
    View in: PubMed
    Score: 0.005
  89. Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol. 2004 Apr; 28(4):489-95.
    View in: PubMed
    Score: 0.005
  90. Myeloid neoplasm with <10% blasts and t(3;5)(q25.1;q34)/NPM::MLF1: A classification dilemma. Am J Hematol. 2024 Sep; 99(9):1827-1829.
    View in: PubMed
    Score: 0.005
  91. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). Blood Cancer J. 2024 02 05; 14(1):25.
    View in: PubMed
    Score: 0.005
  92. Genetics and pathologic landscape of lineage switch of acute leukemia during therapy. Blood Cancer J. 2024 01 25; 14(1):19.
    View in: PubMed
    Score: 0.004
  93. The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research. J Pathol. 2024 03; 262(3):255-270.
    View in: PubMed
    Score: 0.004
  94. Aleukemic Chronic Myeloid Leukemia Without Neutrophilia and Thrombocytosis: A Report From the BCR::ABL1 Pathology Group. Mod Pathol. 2024 Feb; 37(2):100406.
    View in: PubMed
    Score: 0.004
  95. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia. 2024 03; 38(3):545-556.
    View in: PubMed
    Score: 0.004
  96. Optical Genome Mapping Helps to Identify BCR::JAK2 Rearrangement Arising from Cryptic Complex Chromosomal Aberrations: A Case Report and Literature Review. Genes (Basel). 2023 12 08; 14(12).
    View in: PubMed
    Score: 0.004
  97. Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms. Mod Pathol. 2024 Feb; 37(2):100397.
    View in: PubMed
    Score: 0.004
  98. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res. 2023 11 01; 29(21):4352-4360.
    View in: PubMed
    Score: 0.004
  99. Cytogenetic findings in blastoid mantle cell lymphoma. Hum Pathol. 2003 Oct; 34(10):1022-9.
    View in: PubMed
    Score: 0.004
  100. ZNF683 marks a CD8+ T?cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome. Cancer Cell. 2023 10 09; 41(10):1803-1816.e8.
    View in: PubMed
    Score: 0.004
  101. Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma. Mod Pathol. 2023 Dec; 36(12):100326.
    View in: PubMed
    Score: 0.004
  102. Allogeneic cord blood regulatory T cells decrease dsDNA antibody and improve albuminuria in systemic lupus erythematosus. Front Immunol. 2023; 14:1217121.
    View in: PubMed
    Score: 0.004
  103. Cystic sclerosing haemangioma of the lung. Histopathology. 2003 Sep; 43(3):239-43.
    View in: PubMed
    Score: 0.004
  104. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3692-9.
    View in: PubMed
    Score: 0.004
  105. Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T Cells. Cells. 2023 07 18; 12(14).
    View in: PubMed
    Score: 0.004
  106. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J. 2023 06 29; 13(1):101.
    View in: PubMed
    Score: 0.004
  107. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv. 2023 05 23; 7(10):1958-1966.
    View in: PubMed
    Score: 0.004
  108. TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm. Blood Adv. 2023 05 23; 7(10):2000-2003.
    View in: PubMed
    Score: 0.004
  109. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023 Jun; 10(6):e433-e444.
    View in: PubMed
    Score: 0.004
  110. Patterns of Oncogene Coexpression at Single-Cell Resolution Influence Survival in Lymphoma. Cancer Discov. 2023 05 04; 13(5):1144-1163.
    View in: PubMed
    Score: 0.004
  111. Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies. Mod Pathol. 2023 06; 36(6):100166.
    View in: PubMed
    Score: 0.004
  112. Unique pathologic features and gene expression signatures distinguish blastoid high-grade B-cell lymphoma from B-acute lymphoblastic leukemia/lymphoma. Haematologica. 2023 03 01; 108(3):895-899.
    View in: PubMed
    Score: 0.004
  113. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023 02 09; 141(6):567-578.
    View in: PubMed
    Score: 0.004
  114. Composite thymoma and chronic lymphocytic leukemia/small lymphocytic lymphoma involving the anterior mediastinum. Arch Pathol Lab Med. 2003 Feb; 127(2):E76-9.
    View in: PubMed
    Score: 0.004
  115. Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression. J Pathol. 2003 Jan; 199(1):90-7.
    View in: PubMed
    Score: 0.004
  116. Allogeneic cord blood regulatory T cells can resolve lung inflammation. Cytotherapy. 2023 03; 25(3):245-253.
    View in: PubMed
    Score: 0.004
  117. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 2023 Jan; 10(1):e24-e34.
    View in: PubMed
    Score: 0.004
  118. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia. 2022 11; 36(11):2729-2733.
    View in: PubMed
    Score: 0.004
  119. Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases. Haematologica. 2022 09 01; 107(9):2232-2237.
    View in: PubMed
    Score: 0.004
  120. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights. Leuk Res. 2022 10; 121:106928.
    View in: PubMed
    Score: 0.004
  121. Immune pathway upregulation and lower genomic instability distinguish EBV-positive nodal T/NK-cell lymphoma from ENKTL and PTCL-NOS. Haematologica. 2022 08 01; 107(8):1864-1879.
    View in: PubMed
    Score: 0.004
  122. PPP1R7 Is a Novel Translocation Partner of CBFB via t(2;16)(q37;q22) in Acute Myeloid Leukemia. Genes (Basel). 2022 07 29; 13(8).
    View in: PubMed
    Score: 0.004
  123. MUM1/IRF4 is Highly Expressed in Dermatopathic Lymphadenopathy: Potential Utility in Diagnosis and Differential Diagnosis. Am J Surg Pathol. 2022 11 01; 46(11):1514-1523.
    View in: PubMed
    Score: 0.004
  124. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022 07 12; 6(13):4006-4014.
    View in: PubMed
    Score: 0.004
  125. Expression pattern and diagnostic utility of BCL11B in mature T- and NK-cell neoplasms. Pathology. 2022 Dec; 54(7):893-899.
    View in: PubMed
    Score: 0.004
  126. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022 07; 36(7):1720-1748.
    View in: PubMed
    Score: 0.004
  127. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. 2022 11; 35(11):1677-1683.
    View in: PubMed
    Score: 0.004
  128. The utility of epithelial membrane antigen and vimentin in the diagnosis of chromophobe renal cell carcinoma. Ann Diagn Pathol. 2002 Jun; 6(3):154-8.
    View in: PubMed
    Score: 0.004
  129. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. Haematologica. 2022 06 01; 107(6):1311-1322.
    View in: PubMed
    Score: 0.004
  130. Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine. Leuk Res. 2022 08; 119:106884.
    View in: PubMed
    Score: 0.004
  131. Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Adv. 2022 05 24; 6(10):3027-3035.
    View in: PubMed
    Score: 0.004
  132. Nodular Lymphocyte-predominant Hodgkin Lymphoma With Nodular Sclerosis: An Underrecognized Feature Associated With Pattern D. Am J Surg Pathol. 2022 09 01; 46(9):1291-1297.
    View in: PubMed
    Score: 0.004
  133. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Mod Pathol. 2022 09; 35(9):1212-1219.
    View in: PubMed
    Score: 0.004
  134. CD56(+) TdT(+) blastic natural killer cell tumor of the skin: a primitive systemic malignancy related to myelomonocytic leukemia. Cancer. 2002 May 01; 94(9):2401-8.
    View in: PubMed
    Score: 0.004
  135. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol. 2022 07; 97(7):865-876.
    View in: PubMed
    Score: 0.004
  136. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia. 2022 05; 36(5):1343-1350.
    View in: PubMed
    Score: 0.004
  137. From the archives of MD Anderson Cancer Center: Intravascular large B-cell lymphoma with numerous circulating lymphoma cells. Ann Diagn Pathol. 2022 Jun; 58:151934.
    View in: PubMed
    Score: 0.004
  138. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood. 2022 02 10; 139(6):907-921.
    View in: PubMed
    Score: 0.004
  139. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer J. 2022 01 31; 12(1):23.
    View in: PubMed
    Score: 0.004
  140. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J. 2022 01 11; 12(1):5.
    View in: PubMed
    Score: 0.004
  141. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. Am J Hematol. 2022 03 01; 97(3):329-337.
    View in: PubMed
    Score: 0.004
  142. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. 2022 03; 57(3):370-376.
    View in: PubMed
    Score: 0.004
  143. Cyclin D1 expression in Rosai-Dorfman disease: a near-constant finding that is not invariably associated with mitogen-activated protein kinase/extracellular signal-regulated kinase pathway activation. Hum Pathol. 2022 03; 121:36-45.
    View in: PubMed
    Score: 0.004
  144. Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies. Cancer Genet. 2022 04; 262-263:23-29.
    View in: PubMed
    Score: 0.004
  145. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience. Blood Adv. 2021 12 14; 5(23):5415-5419.
    View in: PubMed
    Score: 0.004
  146. Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation. Ann Diagn Pathol. 2022 Feb; 56:151860.
    View in: PubMed
    Score: 0.004
  147. Cell Biology Meets Cell Metabolism: Energy Production Is Similar in Stem Cells and in Cancer Stem Cells in Brain and Bone Marrow. J Histochem Cytochem. 2022 01; 70(1):29-51.
    View in: PubMed
    Score: 0.004
  148. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Adv. 2021 10 26; 5(20):3913-3918.
    View in: PubMed
    Score: 0.004
  149. Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood. 2021 10 14; 138(15):1373-1377.
    View in: PubMed
    Score: 0.004
  150. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol. 2021 11 01; 96(11):1420-1428.
    View in: PubMed
    Score: 0.004
  151. B-prolymphocytic leukemia: Is it time to retire this entity? Ann Diagn Pathol. 2021 Oct; 54:151790.
    View in: PubMed
    Score: 0.004
  152. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer. 2021 09 15; 127(18):3381-3389.
    View in: PubMed
    Score: 0.004
  153. Incidental identification of inv(16)(p13.1q22)/CBFB-MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy. Cold Spring Harb Mol Case Stud. 2021 06; 7(3).
    View in: PubMed
    Score: 0.004
  154. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy. Clin Lymphoma Myeloma Leuk. 2021 11; 21(11):734-740.
    View in: PubMed
    Score: 0.004
  155. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J. 2021 05 20; 11(5):98.
    View in: PubMed
    Score: 0.004
  156. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leuk Lymphoma. 2021 10; 62(10):2400-2407.
    View in: PubMed
    Score: 0.004
  157. Laboratory Evaluation and Pathological Workup of Neoplastic Monocytosis - Chronic Myelomonocytic Leukemia and Beyond. Curr Hematol Malig Rep. 2021 06; 16(3):286-303.
    View in: PubMed
    Score: 0.004
  158. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124.
    View in: PubMed
    Score: 0.004
  159. Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2021 04 01; 106(4):1047-1055.
    View in: PubMed
    Score: 0.004
  160. Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma. Haematologica. 2021 04 01; 106(4):1120-1128.
    View in: PubMed
    Score: 0.004
  161. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer. 2021 08 01; 127(15):2648-2656.
    View in: PubMed
    Score: 0.004
  162. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2021 06 15; 127(12):2025-2038.
    View in: PubMed
    Score: 0.004
  163. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 2021 05 01; 96(5):589-598.
    View in: PubMed
    Score: 0.004
  164. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J. 2021 03 06; 11(3):52.
    View in: PubMed
    Score: 0.004
  165. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. Leukemia. 2021 09; 35(9):2621-2634.
    View in: PubMed
    Score: 0.004
  166. TAM kinases as regulators of cell death. Biochim Biophys Acta Mol Cell Res. 2021 05; 1868(6):118992.
    View in: PubMed
    Score: 0.004
  167. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol. 2021 03; 192(6):1054-1063.
    View in: PubMed
    Score: 0.004
  168. From the archives of MD Anderson Cancer Center: A case of concurrent follicular lymphoma and Langerhans cell sarcoma with a review of the literature. Ann Diagn Pathol. 2021 Jun; 52:151720.
    View in: PubMed
    Score: 0.004
  169. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):338-344.
    View in: PubMed
    Score: 0.004
  170. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax. Leuk Lymphoma. 2021 05; 62(5):1129-1135.
    View in: PubMed
    Score: 0.004
  171. Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. Am J Hematol. 2021 02 01; 96(2):E50-E53.
    View in: PubMed
    Score: 0.004
  172. Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience. Mod Pathol. 2021 05; 34(5):854-861.
    View in: PubMed
    Score: 0.004
  173. Social Media for Hematopathologists: Medical Practice Reinvented-#Hemepath. Curr Hematol Malig Rep. 2020 10; 15(5):383-390.
    View in: PubMed
    Score: 0.004
  174. From the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later. Ann Diagn Pathol. 2021 Feb; 50:151649.
    View in: PubMed
    Score: 0.004
  175. CD123 Expression in Philadelphia Chromosome-like B Acute Lymphoblastic Leukemia/Lymphoma. Clin Lymphoma Myeloma Leuk. 2021 04; 21(4):e317-e320.
    View in: PubMed
    Score: 0.004
  176. A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. J Natl Compr Canc Netw. 2020 10; 18(10):1300-1304.
    View in: PubMed
    Score: 0.004
  177. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma. 2021 01; 62(1):224-228.
    View in: PubMed
    Score: 0.004
  178. Lymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphoma. Ann Diagn Pathol. 2020 Dec; 49:151636.
    View in: PubMed
    Score: 0.004
  179. Hydroa Vacciniforme-Like Lymphoproliferative Disorder With Progression to EBV+ Cytotoxic Peripheral T-Cell Lymphoma. Am J Dermatopathol. 2020 09; 42(9):714-716.
    View in: PubMed
    Score: 0.004
  180. Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics. 2021 05; 16(5):567-576.
    View in: PubMed
    Score: 0.004
  181. Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. Blood Cancer J. 2020 08 26; 10(8):86.
    View in: PubMed
    Score: 0.004
  182. Valve surgery for infective endocarditis complicated by stroke: surgical timing and perioperative neurological complications. Eur J Neurol. 2020 12; 27(12):2430-2438.
    View in: PubMed
    Score: 0.004
  183. Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: A novel finding and possible diagnostic pitfall. J Dermatol. 2020 Oct; 47(10):e354-e355.
    View in: PubMed
    Score: 0.004
  184. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas. Curr Hematol Malig Rep. 2020 08; 15(4):372-381.
    View in: PubMed
    Score: 0.004
  185. Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Am J Hematol. 2020 09; 95(9):E245-E247.
    View in: PubMed
    Score: 0.004
  186. Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. Leuk Lymphoma. 2020 12; 61(13):3243-3246.
    View in: PubMed
    Score: 0.004
  187. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Jul; 7(7):e523-e533.
    View in: PubMed
    Score: 0.004
  188. Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies. Curr Hematol Malig Rep. 2020 06; 15(3):194-202.
    View in: PubMed
    Score: 0.003
  189. Chronic myeloid leukemia with insertion-derived BCR-ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis. Mod Pathol. 2020 10; 33(10):2035-2045.
    View in: PubMed
    Score: 0.003
  190. Phase 2 study of hyper-CMAD with liposomal vincristine for patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2020 07; 95(7):734-739.
    View in: PubMed
    Score: 0.003
  191. Mechanistic basis and efficacy of targeting the ?-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood. 2020 04 09; 135(15):1255-1269.
    View in: PubMed
    Score: 0.003
  192. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol. 2020 09; 33(9):1678-1689.
    View in: PubMed
    Score: 0.003
  193. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622.
    View in: PubMed
    Score: 0.003
  194. T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid. Leukemia. 2020 09; 34(9):2509-2512.
    View in: PubMed
    Score: 0.003
  195. Reconsideration of the first recognition of breast implant-associated anaplastic large cell lymphoma: A critical review of the literature. Ann Diagn Pathol. 2020 Apr; 45:151474.
    View in: PubMed
    Score: 0.003
  196. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP?treated diffuse large B-cell lymphoma. Eur J Haematol. 2020 Apr; 104(4):336-343.
    View in: PubMed
    Score: 0.003
  197. Coactivation of NF-?B and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion. Blood. 2020 01 09; 135(2):108-120.
    View in: PubMed
    Score: 0.003
  198. Clinical, histopathologic, and immunoarchitectural features of dermatopathic lymphadenopathy: an update. Mod Pathol. 2020 06; 33(6):1104-1121.
    View in: PubMed
    Score: 0.003
  199. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood Cancer J. 2019 12 06; 9(12):99.
    View in: PubMed
    Score: 0.003
  200. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol. 2020 02; 95(2):144-150.
    View in: PubMed
    Score: 0.003
  201. Genome-wide analysis of acute leukemia and clonally related histiocytic sarcoma in a series of three pediatric patients. Pediatr Blood Cancer. 2020 02; 67(2):e28074.
    View in: PubMed
    Score: 0.003
  202. Diffuse large B-cell lymphoma variants: an update. Pathology. 2020 Jan; 52(1):53-67.
    View in: PubMed
    Score: 0.003
  203. Liquid Biopsy by Next-Generation Sequencing: a Multimodality Test for Management of Cancer. Curr Hematol Malig Rep. 2019 10; 14(5):358-367.
    View in: PubMed
    Score: 0.003
  204. Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing. Curr Hematol Malig Rep. 2019 10; 14(5):376-385.
    View in: PubMed
    Score: 0.003
  205. Epstein - Barr virus infection in de novo diffuse large B-cell lymphoma in Jordan and Turkey. Ann Diagn Pathol. 2019 Dec; 43:151406.
    View in: PubMed
    Score: 0.003
  206. Chronic lymphocytic leukemia with plasmacytic differentiation. Ann Hematol. 2019 Oct; 98(10):2437-2438.
    View in: PubMed
    Score: 0.003
  207. A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. Mod Pathol. 2020 03; 33(3):367-379.
    View in: PubMed
    Score: 0.003
  208. PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma. Mod Pathol. 2020 03; 33(3):324-333.
    View in: PubMed
    Score: 0.003
  209. Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. Leuk Lymphoma. 2020 01; 61(1):171-175.
    View in: PubMed
    Score: 0.003
  210. Preanalytics and Precision Pathology: Pathology Practices to Ensure Molecular Integrity of Cancer Patient Biospecimens for Precision Medicine. Arch Pathol Lab Med. 2019 11; 143(11):1346-1363.
    View in: PubMed
    Score: 0.003
  211. Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma. Blood Adv. 2019 07 09; 3(13):2035-2039.
    View in: PubMed
    Score: 0.003
  212. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol. 2019 Aug; 41:38-42.
    View in: PubMed
    Score: 0.003
  213. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019 07; 94(7):757-766.
    View in: PubMed
    Score: 0.003
  214. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood. 2019 07 04; 134(1):59-73.
    View in: PubMed
    Score: 0.003
  215. Patient with mixed-phenotype acute leukemia with CBFB rearrangement. Leuk Lymphoma. 2019 11; 60(11):2829-2831.
    View in: PubMed
    Score: 0.003
  216. Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy. Leuk Lymphoma. 2019 10; 60(10):2432-2440.
    View in: PubMed
    Score: 0.003
  217. Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations. Cancer Genet. 2019 04; 233-234:21-31.
    View in: PubMed
    Score: 0.003
  218. A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure. Leuk Lymphoma. 2019 09; 60(9):2207-2213.
    View in: PubMed
    Score: 0.003
  219. Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys. 2019 06 01; 104(2):447-455.
    View in: PubMed
    Score: 0.003
  220. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019 01 15; 9(2):4.
    View in: PubMed
    Score: 0.003
  221. Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue. Clin Lymphoma Myeloma Leuk. 2019 04; 19(4):244-250.
    View in: PubMed
    Score: 0.003
  222. Targeting nuclear ?-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. 2019 06; 33(6):1373-1386.
    View in: PubMed
    Score: 0.003
  223. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. 2019 02 15; 125(4):559-574.
    View in: PubMed
    Score: 0.003
  224. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 2018 Dec; 5(12):e618-e627.
    View in: PubMed
    Score: 0.003
  225. Distinguishing thymoma from T-lymphoblastic leukaemia/lymphoma: a case-based evaluation. J Clin Pathol. 2019 Mar; 72(3):251-257.
    View in: PubMed
    Score: 0.003
  226. Accuracy of diagnosing mantle cell lymphoma and identifying its variants on fine-needle aspiration biopsy. Cancer Cytopathol. 2019 02; 127(1):44-51.
    View in: PubMed
    Score: 0.003
  227. Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. Am J Dermatopathol. 2018 Nov; 40(11):831-835.
    View in: PubMed
    Score: 0.003
  228. Focal Rosai-Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation. Mod Pathol. 2019 01; 32(1):16-26.
    View in: PubMed
    Score: 0.003
  229. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018 10 15; 124(20):4044-4055.
    View in: PubMed
    Score: 0.003
  230. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood Adv. 2018 10 09; 2(19):2491-2504.
    View in: PubMed
    Score: 0.003
  231. Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia. Leukemia. 2019 04; 33(4):931-944.
    View in: PubMed
    Score: 0.003
  232. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clin Lymphoma Myeloma Leuk. 2019 01; 19(1):e51-e61.
    View in: PubMed
    Score: 0.003
  233. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. Hum Pathol. 2018 12; 82:215-231.
    View in: PubMed
    Score: 0.003
  234. Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. Mod Pathol. 2018 11; 31(11):1717-1732.
    View in: PubMed
    Score: 0.003
  235. Breast Implant-Associated Anaplastic Large Cell Lymphoma With Bone Marrow Involvement. Aesthet Surg J. 2018 Jun 13; 38(7).
    View in: PubMed
    Score: 0.003
  236. Epstein-Barr virus-positive follicular lymphoma. Br J Haematol. 2018 09; 182(6):757.
    View in: PubMed
    Score: 0.003
  237. MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas. Mod Pathol. 2018 09; 31(9):1470-1478.
    View in: PubMed
    Score: 0.003
  238. Cerebral microbleeds predict infectious intracranial aneurysm in infective endocarditis. Eur J Neurol. 2018 07; 25(7):970-975.
    View in: PubMed
    Score: 0.003
  239. Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. Am J Surg Pathol. 2018 05; 42(5):569-577.
    View in: PubMed
    Score: 0.003
  240. Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations. Br J Haematol. 2018 05; 181(3):305.
    View in: PubMed
    Score: 0.003
  241. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2018 02; 19(2):240-248.
    View in: PubMed
    Score: 0.003
  242. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol. 2018 03; 93(3):371-374.
    View in: PubMed
    Score: 0.003
  243. Epstein-Barr virus-associated primary nodal T/NK-cell lymphoma shows a distinct molecular signature and copy number changes. Haematologica. 2018 02; 103(2):278-287.
    View in: PubMed
    Score: 0.003
  244. Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood. 2018 01 04; 131(1):84-94.
    View in: PubMed
    Score: 0.003
  245. Sporadic Burkitt Lymphoma Presenting as Intestinal Polyposis in a Child. Appl Immunohistochem Mol Morphol. 2017 10; 25(9):e80-e81.
    View in: PubMed
    Score: 0.003
  246. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. J Cutan Pathol. 2017 Dec; 44(12):1075-1079.
    View in: PubMed
    Score: 0.003
  247. Erythroleukemia-historical perspectives and recent advances in diagnosis and management. Blood Rev. 2018 03; 32(2):96-105.
    View in: PubMed
    Score: 0.003
  248. Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms. Haematologica. 2017 12; 102(12):2048-2057.
    View in: PubMed
    Score: 0.003
  249. Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. Am J Hematol. 2017 10; 92(10):E595-E597.
    View in: PubMed
    Score: 0.003
  250. Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer J. 2017 07 14; 7(7):e583.
    View in: PubMed
    Score: 0.003
  251. BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells. Leukemia. 2018 02; 32(2):343-352.
    View in: PubMed
    Score: 0.003
  252. Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol. 2017 10; 30(10):1367-1377.
    View in: PubMed
    Score: 0.003
  253. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer. 2017 Oct 01; 123(19):3717-3724.
    View in: PubMed
    Score: 0.003
  254. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017 06; 92(6):E114-E117.
    View in: PubMed
    Score: 0.003
  255. Characteristics and clinical implications of reactive germinal centers in the bone marrow. Hum Pathol. 2017 10; 68:7-21.
    View in: PubMed
    Score: 0.003
  256. Herpes simplex infection simulating Richter transformation: a series of four cases and review of the literature. Histopathology. 2017 Apr; 70(5):821-831.
    View in: PubMed
    Score: 0.003
  257. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol. 2017 Apr; 98(4):415-421.
    View in: PubMed
    Score: 0.003
  258. Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. Mod Pathol. 2017 05; 30(5):734-744.
    View in: PubMed
    Score: 0.003
  259. Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):333-338.
    View in: PubMed
    Score: 0.003
  260. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma. Mod Pathol. 2017 02; 30(2):194-203.
    View in: PubMed
    Score: 0.003
  261. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 2017 Feb 15; 123(4):629-637.
    View in: PubMed
    Score: 0.003
  262. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017 01 01; 123(2):294-302.
    View in: PubMed
    Score: 0.003
  263. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer. 2016 Dec 15; 122(24):3812-3820.
    View in: PubMed
    Score: 0.003
  264. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure? Crit Rev Oncol Hematol. 2016 Sep; 105:112-7.
    View in: PubMed
    Score: 0.003
  265. Clinical significance of acquired loss of the X chromosome in bone marrow. Leuk Res. 2016 08; 47:109-13.
    View in: PubMed
    Score: 0.003
  266. Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype. Cancer Genet. 2016 Jul-Aug; 209(7-8):313-20.
    View in: PubMed
    Score: 0.003
  267. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016 06 02; 127(22):2742-50.
    View in: PubMed
    Score: 0.003
  268. Bone Marrow Synoptic Reporting for Hematologic Neoplasms: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med. 2016 Sep; 140(9):932-49.
    View in: PubMed
    Score: 0.003
  269. Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. AJNR Am J Neuroradiol. 1996 Jan; 17(1):79-85.
    View in: PubMed
    Score: 0.003
  270. Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1(+)). Arch Pathol Lab Med. 2016 Jul; 140(7):672-4.
    View in: PubMed
    Score: 0.003
  271. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Myeloproliferative Neoplasms. Arch Pathol Lab Med. 2016 Jul; 140(7):675-7.
    View in: PubMed
    Score: 0.003
  272. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis. Histopathology. 2016 Jun; 68(7):1090-8.
    View in: PubMed
    Score: 0.003
  273. Dyspoietic changes associated with hepatosplenic T-cell lymphoma are not a manifestation of a myelodysplastic syndrome: analysis of 25 patients. Hum Pathol. 2016 Apr; 50:109-17.
    View in: PubMed
    Score: 0.003
  274. Pipeline Embolization Device in the Treatment of Recurrent Previously Stented Cerebral Aneurysms. AJNR Am J Neuroradiol. 2016 May; 37(5):849-55.
    View in: PubMed
    Score: 0.003
  275. Hypoxic preconditioning decreases nuclear factor ?B activity via Disrupted in Schizophrenia-1. Int J Biochem Cell Biol. 2016 Jan; 70:140-8.
    View in: PubMed
    Score: 0.003
  276. De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis. Pediatr Hematol Oncol. 2015; 32(8):535-47.
    View in: PubMed
    Score: 0.003
  277. Clinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of ?d T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With a? T-Cell Large Granular Lymphocytic Leukemia. [corrected]. Am J Clin Pathol. 2015 Oct; 144(4):607-19.
    View in: PubMed
    Score: 0.003
  278. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015 Nov; 16(15):1547-1555.
    View in: PubMed
    Score: 0.003
  279. Crystal-storing histiocytosis: a clinicopathological study of 13 cases. Histopathology. 2016 Mar; 68(4):482-91.
    View in: PubMed
    Score: 0.003
  280. Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications. Oncologist. 2015 Oct; 20(10):1154-60.
    View in: PubMed
    Score: 0.003
  281. Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia. Am J Hematol. 2015 Oct; 90(10):882-7.
    View in: PubMed
    Score: 0.003
  282. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer Genet. 2015 Nov; 208(11):571-4.
    View in: PubMed
    Score: 0.002
  283. Clinical significance of newly emerged isolated del(20q) in patients following cytotoxic therapies. Mod Pathol. 2015 08; 28(8):1014-22.
    View in: PubMed
    Score: 0.002
  284. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia. 2015 Nov; 29(11):2263-6.
    View in: PubMed
    Score: 0.002
  285. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. J Hematol Oncol. 2015 Apr 08; 8:32.
    View in: PubMed
    Score: 0.002
  286. CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. Mod Pathol. 2015 Jun; 28(6):787-98.
    View in: PubMed
    Score: 0.002
  287. Epstein-Barr virus-positive plasmacytoma in immunocompetent patients. Histopathology. 2015 Aug; 67(2):225-34.
    View in: PubMed
    Score: 0.002
  288. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thromb Haemost. 2015 Mar; 113(3):593-8.
    View in: PubMed
    Score: 0.002
  289. MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation. Hum Pathol. 2015 Jan; 46(1):65-73.
    View in: PubMed
    Score: 0.002
  290. Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution. Am J Hematol. 2014 Aug; 89(8):813-8.
    View in: PubMed
    Score: 0.002
  291. Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement. Blood. 2013 Nov 07; 122(19):3387-8.
    View in: PubMed
    Score: 0.002
  292. Urothelial bladder carcinoma with choriocarcinomatous differentiation presenting with a false-positive pregnancy test. Am J Med Sci. 2013 Sep; 346(3):256-8.
    View in: PubMed
    Score: 0.002
  293. Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. Ann Oncol. 2013 Oct; 24(10):2515-2521.
    View in: PubMed
    Score: 0.002
  294. Pediatric cutaneous angiosarcomas: a clinicopathologic study of 10 cases. Am J Surg Pathol. 2011 Jan; 35(1):70-5.
    View in: PubMed
    Score: 0.002
  295. Cholangiocyte apoptosis is an early event during induced metamorphosis in the sea lamprey, Petromyzon marinus L. J Pediatr Surg. 2010 Jan; 45(1):114-20.
    View in: PubMed
    Score: 0.002
  296. Validation of a HOME Injury Survey. Inj Prev. 2009 Oct; 15(5):300-6.
    View in: PubMed
    Score: 0.002
  297. Clonal relationship between precursor B-cell acute lymphoblastic leukemia and histiocytic sarcoma: a case report and discussion in the context of similar cases. Leuk Res. 2010 Feb; 34(2):e71-3.
    View in: PubMed
    Score: 0.002
  298. Met amplification and tumor progression in Cdkn2a-deficient melanocytes. Pigment Cell Melanoma Res. 2009 Aug; 22(4):454-60.
    View in: PubMed
    Score: 0.002
  299. Adenosine signaling mediates SUMO-1 modification of IkappaBalpha during hypoxia and reoxygenation. J Biol Chem. 2009 May 15; 284(20):13686-13695.
    View in: PubMed
    Score: 0.002
  300. Predictive factors of invasion in eyes with retinoblastoma enucleated after eye salvage treatments. Pediatr Blood Cancer. 2009 Mar; 52(3):351-6.
    View in: PubMed
    Score: 0.002
  301. Angiosarcomas arising in the viscera and soft tissue of children and young adults: a clinicopathologic study of 15 cases. Am J Surg Pathol. 2009 Feb; 33(2):264-9.
    View in: PubMed
    Score: 0.002
  302. p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor. Cancer Res. 2009 Jan 15; 69(2):440-8.
    View in: PubMed
    Score: 0.002
  303. Smoking and family history and risk of aneurysmal subarachnoid hemorrhage. Neurology. 2009 Jan 06; 72(1):69-72.
    View in: PubMed
    Score: 0.002
  304. Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res. 2008 Jul 15; 14(14):4572-83.
    View in: PubMed
    Score: 0.002
  305. Prolactinoma as the first manifestation of Gardner's syndrome. Pediatr Blood Cancer. 2008 Feb; 50(2):409-12.
    View in: PubMed
    Score: 0.001
  306. Significance of pleural effusion in neuroblastoma. Pediatr Blood Cancer. 2007 Dec; 49(7):906-8.
    View in: PubMed
    Score: 0.001
  307. Desmoplastic small round cell tumor in childhood: the St. Jude Children's Research Hospital experience. Pediatr Blood Cancer. 2007 Sep; 49(3):274-9.
    View in: PubMed
    Score: 0.001
  308. MRI and biologic behavior of desmoid tumors in children. AJR Am J Roentgenol. 2007 Sep; 189(3):633-40.
    View in: PubMed
    Score: 0.001
  309. Telangiectatic osteosarcoma: the St. Jude Children's Research Hospital's experience. Cancer. 2007 Apr 15; 109(8):1627-37.
    View in: PubMed
    Score: 0.001
  310. St. Jude Children's Research Hospital, Memphis, Tennessee: gestational choriocarcinoma. Pediatr Blood Cancer. 2006 Oct 15; 47(5):640-6.
    View in: PubMed
    Score: 0.001
  311. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Mol Cancer Ther. 2006 May; 5(5):1299-308.
    View in: PubMed
    Score: 0.001
  312. Osteosarcoma among children aged 5 years or younger: the St. Jude Children's Research Hospital experience. J Pediatr Hematol Oncol. 2006 Jan; 28(1):43-7.
    View in: PubMed
    Score: 0.001
  313. Activation status of the JAK/STAT3 pathway in mantle cell lymphoma. Arch Pathol Lab Med. 2005 Aug; 129(8):990-6.
    View in: PubMed
    Score: 0.001
  314. Chromophobe renal cell carcinoma: a comparative study of histological, immunohistochemical and ultrastructural features using high throughput tissue microarray. Histopathology. 2004 Dec; 45(6):593-602.
    View in: PubMed
    Score: 0.001
  315. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood. 2004 Jul 15; 104(2):328-35.
    View in: PubMed
    Score: 0.001
  316. Trends and patterns of playground injuries in United States children and adolescents. Ambul Pediatr. 2001 Jul-Aug; 1(4):227-33.
    View in: PubMed
    Score: 0.001
  317. Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset. AJNR Am J Neuroradiol. 2001 Apr; 22(4):685-90.
    View in: PubMed
    Score: 0.001
  318. Bizarre parosteal osteochondromatous proliferation of bone (BPOP): an unusual foot mass in a child. Foot Ankle Int. 2000 May; 21(5):404-7.
    View in: PubMed
    Score: 0.001
  319. Protein metabolism in insulin-treated gestational diabetes. Diabetes Care. 1999 May; 22(5):806-11.
    View in: PubMed
    Score: 0.001
  320. Acute stroke: delays to presentation and emergency department evaluation. Ann Emerg Med. 1999 Jan; 33(1):3-8.
    View in: PubMed
    Score: 0.001
  321. A prospective analysis of serum vitamin K in severely burned pediatric patients. J Burn Care Rehabil. 1998 Jan-Feb; 19(1 Pt 1):75-81; discussion 73-4.
    View in: PubMed
    Score: 0.001
  322. Ragweed immunotherapy in adult asthma. N Engl J Med. 1996 Feb 22; 334(8):501-6.
    View in: PubMed
    Score: 0.001
  323. [Myocardial infarction hospital survival. Multicenter study of 201 patients in 1993]. J Med Liban. 1995; 43(3):131-4.
    View in: PubMed
    Score: 0.001
  324. The prognostic value of nutritional and inflammatory indices in patients with burns. J Burn Care Rehabil. 1992 Jan-Feb; 13(1):105-13.
    View in: PubMed
    Score: 0.000
  325. [Abdomen perforating wounds. Study of 61 cases (author's transl)]. Med Trop (Mars). 1982 Mar-Apr; 42(2):169-72.
    View in: PubMed
    Score: 0.000
  326. Treatment of chronic radiation enteritis and colitis with salicylazosulfapyridine and systemic corticosteroids. A pilot study. Am J Gastroenterol. 1976 Mar; 65(3):201-8.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.